ENDOSYME OBI

Serial Number 98287135
Registration 7933685
700

Registration Progress

Application Filed
Nov 27, 2023
Under Examination
Oct 1, 2024
Approved for Publication
Aug 6, 2024
Published for Opposition
Jul 22, 2025
Registered
Sep 9, 2025

Trademark Image

ENDOSYME OBI

Basic Information

Serial Number
98287135
Registration Number
7933685
Filing Date
November 27, 2023
Registration Date
September 9, 2025
Published for Opposition
July 22, 2025
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Sep 9, 2025
Registration
Registered
Classes
005

Rights Holder

OBI PHARMA, INC.

03
Address
6F., No. 508, Sec. 7, Zhongxiao E. Rd.,
Nangang Dist.,
Taipei City 115011
TW

Ownership History

OBI PHARMA, INC.

Original Applicant
03
Taipei City TW

OBI PHARMA, INC.

Owner at Publication
03
Taipei City TW

OBI PHARMA, INC.

Original Registrant
03
Taipei City TW

Legal Representation

Attorney
Ran He

USPTO Deadlines

Next Deadline
2087 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250909)
Due Date
September 09, 2031
Grace Period Ends
March 09, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

29 events
Date Code Type Description Documents
Sep 9, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Sep 9, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jul 22, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 22, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 16, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 27, 2025 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Loading...
Apr 10, 2025 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Loading...
Feb 24, 2025 OTHE I CASE RETURNED TO EXAMINATION Loading...
Feb 24, 2025 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
Feb 14, 2025 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
Feb 14, 2025 PCBG O PETITION TO DIRECTOR - CHANGE BASIS - GRANTED Loading...
Feb 13, 2025 APET A ASSIGNED TO PETITION STAFF Loading...
Jan 3, 2025 TPAD I TEAS PETITION TO AMEND BASIS RECEIVED Loading...
Oct 1, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 6, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 6, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 17, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 27, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 27, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jun 27, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jun 27, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jun 27, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jun 26, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 26, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Mar 26, 2024 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Mar 26, 2024 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jan 19, 2024 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Jan 18, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 1, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Immunostimulants; Vaccines; Adjuvants for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Chemical reagents for medical or veterinary purposes; Enzyme preparations for medical purposes; Enzymes for medical purposes; Ferments for pharmaceutical purposes; Hormones for medical purposes; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Preparations of microorganisms for medical purposes; Tumor suppressing agents

Additional Information

Design Mark
The mark consists of the black stylized wording "EndoSyme" and the teal stylized wording "OBI"with a curved teal line below "OBI".
Color Claim
The color(s) black and teal is/are claimed as a feature of the mark.

Classification

International Classes
005